scholarly journals Clinical use of recombinant human TSH in thyroid cancer patients

2000 ◽  
pp. 557-563 ◽  
Author(s):  
M Schlumberger ◽  
M Ricard ◽  
F Pacini
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Hormone ◽  
Cancer Patients ◽  
Recurrent Disease ◽  
Clinical Use ◽  
Follicular Thyroid Cancer ◽  
Safe Alternative ◽  
Thyroid Hormone Withdrawal ◽  
Recombinant Human Tsh

Recombinant human TSH (rhTSH) is an effective and safe alternative to thyroid hormone withdrawal during the post-surgical follow-up of papillary and follicular thyroid cancer. Its clinical efficiency for the detection of persistent and recurrent disease is similar to that of thyroid hormone withdrawal. The main purpose for its use is to avoid hypothyroidism.

scholarly journals Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal

2007 ◽  
Vol 156 (5) ◽  
pp. 531-538 ◽  
Author(s):  
I Borget ◽  
C Corone ◽  
M Nocaudie ◽  
M Allyn ◽  
S Iacobelli ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Hormone ◽  
Sick Leave ◽  
Cancer Patients ◽  
Human Thyroid ◽  
Thyroid Hormone Withdrawal ◽  
The Mean ◽  
The Cost ◽  
Active Patients

Introduction: The clinical benefits of recombinant human thyroid-stimulating hormone (rhTSH; Thyrogen) are well established as an alternative stimulation procedure to thyroid hormone withdrawal in the diagnostic follow-up of thyroid cancer patients. By avoiding periods of hypothyroidism, patients do not suffer from a decreased quality of life and keep their ability to work. This study compared the frequency, the duration and the cost of sick leave for follow-up control between rhTSH and withdrawal. Methods: The study population consisted of patients with thyroid carcinoma first treated by thyroidectomy and radioiodine ablation. Patients were recruited at their control visit between October 2004 and May 2006 in three hospitals, both prospectively and retrospectively. Collection data consisted of patient information, job characteristics and duration of sick leave during the month before and the month after control. The valuation of sick leave used the friction cost method. Results: Among the 306 patients included, 292 (95%) completed the entire questionnaire. The mean age was 46.7 years. Among the 194 active patients, patients treated with rhTSH, when compared with patients treated by withdrawal, were less likely to require sick leave (11 vs 33%; P=0.001). The mean duration of sick leave was shorter (3.1 vs 11.2 days; P=0.002) and indirect costs due to absenteeism accounted for €454 ± 1673 vs €1537 ± 2899 for withdrawal stimulation. Conclusion: For active patients, rhTSH treatment reduced the length and the cost of sick leave by 8.1 days and €1083 per control respectively, when compared with withdrawal treatment.

scholarly journals Five-Year Survival Is Similar in Thyroid Cancer Patients with Distant Metastases Prepared for Radioactive Iodine Therapy with either Thyroid Hormone Withdrawal or Recombinant Human TSH

2011 ◽  
Vol 96 (7) ◽  
pp. 2105-2111 ◽  
Author(s):  
H. Tala ◽  
R. Robbins ◽  
J. A. Fagin ◽  
S. M. Larson ◽  
R. M. Tuttle
Keyword(s):  
Overall Survival ◽  
Thyroid Cancer ◽  
Thyroid Hormone ◽  
Cancer Patients ◽  
Metastatic Disease ◽  
Tertiary Care ◽  
Distant Metastases ◽  
Comprehensive Cancer Center ◽  
Thyroid Hormone Withdrawal ◽  
Recombinant Human Tsh

Abstract Context: Elevated levels of TSH markedly enhance the effectiveness of radioiodine (RAI) therapy in metastatic thyroid cancer. Objective: The objective of the study was to compare short-term overall survival in thyroid cancer patients with RAI-avid distant metastases prepared for RAI therapy with either traditional thyroid hormone withdrawal (THW) or recombinant human TSH (rhTSH) stimulation. Design: This was a retrospective chart review. Setting: The study was conducted at a tertiary care comprehensive cancer center. Patients: Patients included 175 patients with RAI avid metastatic disease to lung and/or bone. Interventions: In 58 patients, all RAI treatments (remnant ablation and therapy of metastatic disease) were done with rhTSH stimulation. In 35 patients, all RAI treatments were done after THW. In 82 patients, THW was used for initial RAI treatment(s) with subsequent administered activities given after rhTSH stimulation. Main Outcome Measure: Overall survival was measured. Results: After a median follow-up of 5.5 yr, there were no significant differences in overall survival between patients prepared for RAI therapy with rhTSH alone, THW alone, or THW followed by rhTSH (Kaplan-Meier analysis,P = 0.80). In a multivariate analysis that included clinicopathological features and method of preparation (rhTSH or TWH), only age at diagnosis was an independent predictor of overall survival. Conclusions: Preparation for RAI therapy using either THW or rhTSH stimulation was associated with similar 5-yr overall survival rates in patients with RAI avid thyroid cancer metastases to lung or bone.

Sign in / Sign up

Export Citation Format

Share Document